Genetica Medica, Dipartimento di Scienze Biomediche, Università degli Studi di Foggia, Foggia, Italy.
Clin Chem Lab Med. 2010 Dec;48 Suppl 1:S41-51. doi: 10.1515/CCLM.2010.361. Epub 2010 Oct 29.
Venous thrombosis (VT) represents a common and serious disorder that occurs as the result of clotting of the blood in the venous system and venous obstruction. Environmental risk factors and genetic predisposition play an important role in the development of thrombosis. It is therefore seen as a classic example of a complex common disease. We have focused on the role of genetic risk factors, primarily related to the hemostatic system, in triggering thrombotic events. Since the identification of antithrombin deficiency in 1965, major efforts have been made during the past 15 years to identify other genetic entities that lead to increased thrombotic risk. Results of early genetic studies demonstrated that two types of genetic defects cause VT: loss of function mutations in the natural anticoagulants antithrombin, protein C and protein S and gain of function mutations in procoagulant factors V (FV Leiden) and II (prothrombin G20210A). The high incidence of these mutations in Caucasians induced a shift from family studies to case-control association studies. Several investigations have been performed on the role of other candidate genetic risk factors predisposing to VT, including such variants in FXIII, FIX and fibrinogen genes. Moreover, the contribution of genetic variation in genes encoding less-well studied proteins that are part of the anticoagulant pathways has been evaluated. Recently, different genome-wide association studies have been performed in which several single nucleotide polymorphisms were investigated and related to the risk of VT. However, further studies are needed to identify additional genetic causes of thrombosis and to assess functional molecular mechanisms.
静脉血栓形成(VT)是一种常见且严重的疾病,是由于血液在静脉系统中凝结和静脉阻塞而引起的。环境风险因素和遗传易感性在血栓形成的发展中起着重要作用。因此,它被视为一种典型的复杂常见疾病。我们专注于遗传风险因素在引发血栓事件中的作用,主要与止血系统有关。自 1965 年发现抗凝血酶缺乏以来,在过去的 15 年中,人们做出了巨大努力来确定导致血栓形成风险增加的其他遗传实体。早期遗传研究的结果表明,有两种类型的遗传缺陷会导致 VT:天然抗凝剂抗凝血酶、蛋白 C 和蛋白 S 的功能丧失突变,以及促凝血因子 V(FV Leiden)和 II(凝血酶原 G20210A)的功能获得性突变。这些突变在白种人中的高发生率促使人们从家族研究转向病例对照关联研究。已经对其他易导致 VT 的候选遗传风险因素(包括 FXIII、FIX 和纤维蛋白原基因中的变异)的作用进行了多项研究。此外,还评估了遗传变异在编码抗凝途径中部分研究较少的蛋白质的基因中的作用。最近,进行了不同的全基因组关联研究,其中研究了几个单核苷酸多态性,并与 VT 的风险相关。然而,还需要进一步的研究来确定血栓形成的其他遗传原因,并评估功能分子机制。